This white paper examines the evolving landscape of designer and emerging drugs, and the challenges they present for laboratories, clinicians, educators, and institutions. It highlights where traditional resources fall short and outlines evidence-based strategies organizations use to reduce misinterpretation, improve decision-making, and manage risk in rapidly changing drug environments.
Abstract
Designer and emerging drugs, sometimes also referred to as new (or novel) psychoactive substances (NPS), have become more common over the past 20-25 years, resulting in more diverse drug markets than previous years. The most common substances introduced include synthetic cannabinoids, cathinones, opioids, and benzodiazepines. They are created to mimic either traditional illicit substances or scheduled drugs, with the goal of evading the existing regulatory framework. In addition to these classes, there are other substances, such as xylazine and medetomidine, which have also contributed to the exposure risk of the illicit supply. The toxicity and potency of current NPS, polysubstance use, and rapid market changes continue to challenge clinical care, laboratory detection, harm-reduction services, and regulation. This white paper discusses historical trends, motivations for NPS synthesis and use, known geographies, health impacts, and a discussion of mitigation strategies, including drug testing, policy, and harm reduction.
Who This White Paper Is For
This white paper is intended for organizations and professionals who routinely encounter emerging and designer drugs but lack consolidated, clinically grounded resources to support interpretation, education, or risk mitigation.
Primary audiences include:
- Toxicology and drug testing laboratories
- Medical practices and health systems
- Universities and professional training programs
- Medical publishers and continuing education providers
Why This White Paper Exists
Emerging and designer drugs evolve faster than standard reference texts, guidelines, and regulatory updates. As a result, clinicians, laboratories, and educators are often forced to rely on fragmented or outdated information when making decisions with clinical, legal, or educational consequences.
This white paper was developed to:
- Bridge gaps between published literature and real-world practice
- Provide clinically relevant context beyond detection thresholds alone
- Support organizations navigating uncertainty, misinterpretation, and risk
How Organizations Use This White Paper
Organizations use this white paper as:
- A foundational briefing document for internal teams
- A reference framework for developing policies, education, or training
- A starting point for deeper advisory or consultative engagement
- A tool to identify gaps in current knowledge, protocols, or content
The white paper is designed to inform, not replace, expert interpretation.
Organizations seeking ongoing support related to designer or emerging drugs, interpretation, or educational development may inquire about advisory retainers tailored to their needs.
Full White Paper available upon request.